Caris Life Sciences CAI
NASDAQ CAI
$24.79 -0.53 (-2.09%)
As of: Sep 4, 2026 · 11:46 AM EDT

Caris Life Sciences (CAI) Non Operating Interest Expenses (2024 - 2026)

Analysis

Caris Life Sciences (CAI) Non Operating Interest Expenses (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 140.12 Bn 132.26 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 86.04 Bn 78.04 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.63 Bn 58.45 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.45 Bn 52.31 Bn 52.00 Mn -
5 Revolution Medicines 44.06 Bn 44.06 Bn - 23.78 Mn
6 BeOne Medicines 40.14 Bn 35.04 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.29 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.62 Bn 27.79 Bn - 93.62 Mn
9 Insmed 27.73 Bn 26.57 Bn 358.27 Mn 20.27 Mn
10 Caris Life Sciences 7.01 Bn 6.22 Bn 182.38 Mn 9.23 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 9.23 Mn
Mar 31, 2026 12.81 Mn
Dec 31, 2025 11.36 Mn
Sep 30, 2025 13.51 Mn
Jun 30, 2025 19.21 Mn
Mar 31, 2025 12.78 Mn
Dec 31, 2024 13.26 Mn
Sep 30, 2024 13.80 Mn
Jun 30, 2024 13.67 Mn